Biphasic effects of 17-beta-estradiol on expression of occludin and transendothelial resistance and paracellular permeability in human vascular endothelial cells.
Tight junctions govern the paracellular permeability of endothelial and epithelial cells. Aberrations of tight junction function are an early and key event during the vascular spread of cancer and inflammation. This study sought to determine the role of estrogen in the regulation of tight junctions and expression of molecules making tight junctions in endothelial cells. Human endothelial cell, HECV, which express ER-beta but not ER-alpha was used. 17-beta-estradiol induced a concentration- and time-dependent biphasic effect on tight junction. At 10(-9) and 10(-6) M, it decreased the level of occludin and increased in paracellular permeability of HECV cells, but at 10(-12) M it decreased in paracellular permeability and increased the level of occludin. The transendothelial electrical resistance (TER), however, was reduced by 17-beta-estradiol at lower concentrations (as low as 10(-12) M). Furthermore, the time-dependent biphasic effect was observed over a period of 4 days, with the first reduction of TER seen within 15 min and the second drop occurring 48 h after 17-beta-estradiol treatment. It was further revealed that protein and mRNA levels of occludin, but not claudin-1 and -5, and ZO-1, were reduced by 17-beta-estradiol, in line with changes of TER. This study shows that 17-beta-estradiol can induce concentration- and time-related biphasic effects on tight junction functions expression of occludin in endothelial cells and that this perturbation of tight junction functions may have implications in the etiology of mastalgia and the vascular spread of breast cancer.
Ye
Lin
L
Metastasis Research Group, University Department of Surgery, University of Wales College of Medicine, Cardiff, United Kingdom.
Martin
Tracey A
TA
Parr
Christian
C
Harrison
Gregory M
GM
Mansel
Robert E
RE
Jiang
Wen G
WG
D002199:Capillary Permeability / Q000187:drug effects*; D002460:Cell Line; D062445:Claudin-1; D062507:Claudin-5; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism / Q000502:physiology*; D004958:Estradiol / Q000494:pharmacology*; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D005455:Fluorescent Antibody Technique; D006801:Humans; D008565:Membrane Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D062793:Occludin; D012333:RNA, Messenger / Q000037:antagonists & inhibitors; D011960:Receptors, Estrogen / Q000378:metabolism; D013194:Staining and Labeling; D019108:Tight Junctions / Q000187:drug effects / Q000378:metabolism; D014655:Vascular Resistance / Q000187:drug effects*
C568108:CLDN1 protein, human; C107466:CLDN5 protein, human; D062445:Claudin-1; D062507:Claudin-5; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D008565:Membrane Proteins; C568985:OCLN protein, human; D062793:Occludin; D012333:RNA, Messenger; D011960:Receptors, Estrogen; D004958:Estradiol